Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals (ARWR) stays on a bullish path with a HC Wainwright “Buy” rating, strong gene‑silencing pipeline, and a growing anti‑aging market that could boost its long‑term growth.

Arrowhead Pharmaceuticals reports a strong Q1 2026 earnings surge, launches its first U.S. product REDEMPLO®, and expands its gene‑silencing cardiometabolic pipeline, positioning the biotech firm for sustained growth.

Arrowhead Pharmaceuticals’ plozasiran earns FDA Breakthrough Therapy status, sparking analyst upgrades and a fresh bullish outlook on the gene‑silencing biopharma stock.

Arrowhead Pharmaceuticals lands a $200 million milestone from Sarepta for its DM1 RNAi therapy, boosting finances and pipeline prospects.

Arrowhead Pharmaceuticals Inc. has secured a major licensing deal with Novartis, valued at up to $2 billion, granting Novartis exclusive global rights to Arrowhead’s ARO-SNCA therapy for neurodegenerative diseases.

Arrowhead Pharmaceuticals Inc is a pioneering biotech company that is revolutionizing the field of gene silencing, with a focus on developing innovative treatments for intractable diseases and a strong market presence.

Arrowhead Pharmaceuticals Inc, a biotech company with a market cap of $3.01 billion, stands at a critical juncture, balancing its innovative approach to gene-targeting medicines with significant financial and regulatory challenges.

Arrowhead Pharmaceuticals is a biotech company specializing in gene silencing technologies, working to develop innovative treatments for intractable diseases and improve patient outcomes.

Arrowhead Pharmaceuticals is a pioneering biotech company that is leading the charge in gene silencing technologies, with a promising future and potential to transform the healthcare sector.

Arrowhead Pharmaceuticals, Inc. is a pioneering biotech company that is transforming the treatment of intractable diseases through its innovative gene-silencing technologies.